Therapeutic and Diagnostic Targets for Severe RSV Infection


Respiratory Syncytial Virus (RSV) infects nearly all children by their second birthday. RSV usually causes mild respiratory illness, however, a subset of patients experience severe infection that require hospitalization. Successful host defense against viral pathogens requires rapid recognition of the virus and activation of both innate and adaptive immunity. Toll-Like Receptors (TLRs) are responsible for mounting an innate immune response and genetic variations within TLRs modulate severity of infection. Researchers at NIEHS have identified a single nucleotide polymorphism (SNP) in TLR8 that is associated with RSV disease severity. The SNP is p53-responsive allele, indicating that p53, a master cell cycle regulator, can strongly influence TLR8 mediated immune responses. Identification of this SNP can inform diagnosis and prognosis of RSV disease and serve as a therapeutic target for severe RSV infection.

Potential Commercial Applications: Competitive Advantages:
  • Development of therapeutics against severe RSV infection
  • Diagnostic biomarker
 
  • Enhance the innate immune response to respiratory infection
  • Improve clinical trial outcome in patients with TLR8 mediated RSV infection


Inventors:

Michael Resnick (NIEHS)  ➽ more inventions...

Daniel Menendez Rendon (NIEHS)  ➽ more inventions...

Steven Kleeberger (NIEHS)  ➽ more inventions...


Intellectual Property:
US Application No. 62/881,656

Licensing Contact:
Vidita Choudhry, Ph.D.
Email: vidita.choudhry@nih.gov
Phone: 301-594-4095

OTT Reference No: E-072-2019-0
Updated: Feb 6, 2020